Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT) by Albers, James W. et al.
We used electrophysiologic criteria to identify median mononeuropa- 
thy (MM) at the nondominant wrist among 414 patients enrolled in a 
multicenter study of patients with mild diabetic neuropathy according 
to consensus recommendations. Patients with absent sural or peroneal 
responses or greater than mild symptoms of carpal tunnel syndrome 
were ineligible. Ninety-five of 414 participants (23%) fulfilled criteria for 
MM, independent of diabetes type. Patients with MM had a longer du- 
ration of diabetes than remaining patients, independent of age, and 
patients with MM and type II diabetes were more likely to be female 
(34% vs. 19%; P = 0.008), shorter (165.7 vs. 172.7 cm; P = 0.001), and 
have a higher body mass index (32.5 vs. 29.1 : P = 0.0008) than remain- 
ing type II patients. Sural or peroneal conduction abnormalities did not 
influence the frequency of MM. These results suggest that patients with 
diabetic neuropathy require special consideration with regard to the 
evaluation of suspected carpel tunnel syndrome. 0 1996 John Wiley & 
Sons, Inc. 
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FREQUENCY OF MEDIAN 
MONONEUROPATHY IN PATIENTS 
WITH MILD DIABETIC NEUROPATHY 
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JAMES W. ALBERS, MD, PhD, MORTON B. BROWN, PhD, 
ANDERS A. F. SIMA, MD, PhD, and DOUGLAS A. GREENE, MD, FOR THE 
TOLRESTAT STUDY GROUP FOR EDIT (EARLY DIABETES INTERVENTION TRIAL) 
T h e  lifetime risk of developing carpal tunnel syn- 
drome (CTS), a commonly identified mononeur- 
opathy, is approximately lo%." The clinical diag- 
nosis of CTS depends upon a combination of 
appropriate clinical symptoms, with or without as- 
sociated signs. Because symptoms associated with a 
variety of musculoskeletal disorders mimic those of 
CTS, most clinicians require electrophysiologic 
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confirmation of a median mononeuropathy at the 
wrist (MM) before establishing a diagnosis of CTS. 
Nevertheless, use of increasingly sensitive criteria 
results in an increased frequency of false-positive 
results." The revalence of MM is higher in dia- 
betic patients," but this finding is not thought to 
influence the electrodiagnostic criteria of CTS. l 5  
We report the frequency of MM in a popula- 
tion of patients with types I and 11 diabetes and 
mild diabetic neuropathy participating in a multi- 
center study. We used absolute median motor and 
sensory distal latency criteria, combined with the 
difference between median and ulnar sensory dis- 
tal latencies (relative to criteria) to identify MM. 
The relative criteria are thought to be less sensitive 
to factors such as age, temperature, and anthropo- 
metric characteristics because individual median 
and ulnar nerves share the same general environ- 
ment, differing only in their location relative to the 
carpal tunnel. We also investigated the relation- 
ships between the relative risk for MM and factors 
thought to be associated wit1 I increased risk for 
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development of CTS, including body mass index 
(BMI) and lower limb nerve conduction results 
suggestive of generalized n e ~ r o p a t h y . ~ ~  
METHODS 
Study Design. All patients were enrolled in a 
large, double-blind, placebo-controlled random- 
ized study of the effects of tolrestat in patients with 
diabetic neuropathy. The trial design is described 
e1~ewhere.l~ All data were collected prior to ran- 
domization and initiation of therapy. 
Patients. Eligibility required types I or I1 diabetes 
mellitus as classified by the National Diabetes Data 
Group." Diabetic neuropathy was defined as a dis- 
tal symmetric sensorimotor polyneuropathy using 
recommendations of the San Antonio Conference 
on Diabetic N e ~ r o p a t h y . ~  Exclusions included a 
glycosylated hemoglobin less than 6.7% at the ini- 
tial evaluation, a systemic illness other than diabe- 
tes associated with neuropathy, familial neuropa- 
thy, and a mononeuropathy other than a mild CTS 
(based upon the clinical experience of the examin- 
ing neurologist). Patients with severe neuropathy 
were excluded by requiring recordable sural and 
peroneal responses. The diagnosis of clinically ev- 
ident or subclinical diabetic neuropathy was based 
upon two or more abnormalities from the catego- 
ries of symptoms, signs, electrodiagnostic studies, 
and quantitative sensory testing. Symptom and dis- 
ability assessments were used to score symptoms 
and signs." Symptoms had to be consistent with a 
symmetric sensory or  sensorimotor neuropathy. 
Nerve conduction abnormalities used to assess di- 
abetic neuropathy were based upon sural and pe- 
roneal (not median) measures. Vibration percep- 
tion threshold was measured at the great toe using 
a two-alternative forced-choice procedure; pa- 
tients with a substantially elevated threshold were 
ineligible. Height and weight were measured, and 
BMI was calculated as weight (kg)/[height (m)I2. 
Subgroups based upon the BMI were created as 
follows: slender, BMI < 20; normal, BMI 20-24; 
heavy, BMI 25-29; and obese, BMI 3 30.5 
Nerve Conduction Measures. At 41 centers, elec- 
tromyographers used techniques recommended by 
the Conference of Standardized Measures in Dia- 
betic Neuropathy to evaluate dominant peroneal, 
nondominant median motor and sensory, and bi- 
lateral sural responses.6 The peroneal and sural 
recording techniques are described elsewhere.Ig 
Median motor and sensory conduction studies 
used conventional techniques of supramaximal 
stimulation and surface recording. Upper extrem- 
ity limb temperatures were maintained above 
32"C, recorded over the midpalm. Hand temper- 
atures measured before and immediately after 
completing the conduction study were averaged 
and did not differ by diabetes type or gender. 
Median motor onset latency was recorded using 
a distance of 7 cm from stimulation to recording 
electrode (wrist to thenar recording site). Anti- 
dromic sensory peak latency was measured using a 
stimulation to recording electrode distance of 14 
cm (wrist to index finger). If the median motor 
latency exceeded 4.4 ms or the median sensory la- 
tency exceeded 3.8 ms, an antidromic ulnar sen- 
sory peak latency (wrist to digit V, 14 cm) was re- 
corded to apply the relative criteria. Patients had 
three evaluations approximately 1 week apart be- 
fore beginning therapy. Because most clinical de- 
cisions are based upon a single electrodiagnostic 
evaluation, we established the diagnosis of MM us- 
ing results from the first complete evaluation. Pa- 
tients were included if their absolute criteria were 
normal or, if abnormal, the relative criteria were 
evaluated. A total of 389 studies were included 
from the first visit and another 25 were included 
from the first subsequent visit for which data col- 
lection was complete. Another 15 patients had in- 
complete data at all three visits and were excluded 
from all analyses. 
Two criteria for the diagnosis of MM were eval- 
uated. Both required an absolute prolongation of 
median sensory or motor latencies (>3.8 and 4.4 
ms, In addition, the first criterion 
required a difference between the median and ul- 
nar sensory peak latencies exceeding 0.5 ms. This 
relative difference is used conventionally in the di- 
agnosis of MM','4,'6 and represents the 95th per- 
centile for asymptomatic subjects without exposure 
to cumulative trauma.22 The second criterion re- 
quired a relative median to ulnar sensory latency 
difference exceeding 0.8 ms. This more conserva- 
tive criterion represents the 99th percentile for 
asymptomatic subjects without exposure to cumu- 
lative trauma.22 
Statistical Analyses. Summary statistics are pre- 
sented as the median and the 5th and 95th per- 
centiles. Means of groups were compared by a 
two-sample t-test, after transformation where indi- 
cated; P-values in the tables are the results of com- 
paring normals to abnormals separately within 
each diabetes type. When two proportions were 
compared, Fisher's Exact Test (two-tailed) was 
used. When more than two proportions were com- 
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pared, a linear trend in the proportions was tested 
by the Mantel-Haenszel chi-square statistic. 
RESULTS 
The characteristics of the diabetic patients have 
been described previously for the entire cohort.* 
Patients with type I1 diabetes were significantly 
older and heavier and had a higher BMI than type 
I patients, but the duration of symptomatic neu- 
ropathy and glycosylated hemoglobin levels were 
similar. The male patients were heavier and taller 
than the female patients but had a similar BMI. 
Based upon the absolute criterion of a pro- 
longed median sensory or  motor distal latency, 138 
of the 414 patients (33%) demonstrated an abnor- 
mal result. Most abnormalities resulted from a pro- 
longed median sensory latency, with or without 
prolongation of the motor latency; only 6 patients 
had a prolonged median motor but normal me- 
dian sensory latency. According to the additional 
conventional criteria for MM, which included a 
median minus ulnar sensory latency >0.5 ms, 95 
(23%) of 414 participants continued to be abnor- 
mal. When the more conservative relative criterion 
of a median minus ulnar sensory latency >0.8 ms 
was used, 68 (16%) of 414 participants fulfilled the 
criteria for MM. Of the 6 patients with a prolonged 
median motor but normal median sensory laten- 
cies, only 1 had a relative prolongation of the me- 
dian sensory latency compared to the ulnar sen- 
sory latency. 
The characteristics of patients fulfilling con- 
ventional criteria for MM are compared with those 
of the remaining patients in Table 1. The data are 
shown separately for patients with type I and type 
I1 diabetes mellitus. Although type I1 patients 
were older than type I patients, the frequency of 
MM was similar in the two groups. Within each 
group, there was no significant difference in age 
between patients with and without MM. Patients 
with MM had a longer duration of diabetes melli- 
tus than patients without MM (type I, 22.5 vs. 16.0 
years, P = 0.003; type 11, 8.8 vs. 7.0 years, P = 
0.034). Type I1 patients with MM were shorter 
(165.7 vs. 172.7 cm; P = 0.001) and had a higher 
BMI (32.5 vs. 29.1; P = 0.0008) than the remain- 
ing type I1 patients. Neither height nor BMI dif- 
fered significantly among type I diabetic patients 
with or without MM, although the influence of 
height upon the presence of MM became impor- 
tant for patients with either type of diabetes when 
the more conservative definition of MM (absolute 
plus relative criteria of median minus ulnar sen- 
sory latency >0.8 ms) was used. For both groups, 
patients fulfilling the conservative definition of 
MM were shorter than the remaining patients 
(type I, 168.9 vs. 172.0 cm, P = 0.07; type 11, 163.8 
vs. 172.7 cm, P = 0.0005). 
Table 2 compares the frequency of MM by gen- 
der, BMI, and abnormal lower extremity nerve 
conduction frequencies for the type I and type I1 
patient groups. In both groups, women were more 
likely than men to fulfill criteria for MM. In addi- 
tion, there was a tendency for the frequency of 
MM to increase with increasing BMI, although the 
relationship reached statistical significance only for 
type I1 patients. There was no difference in the 
frequency of MM among patients separated into 
groups based upon sural and peroneal nerve con- 
duction studies (normal or  abnormal). Table 3 
compares the nerve conduction results for patients 
fulfilling conventional criteria for MM with the re- 
sults for the remaining patients by diabetes type. 
None of the lower limb measures differed signifi- 
cantly between patients with and without MM for 
patients with either type I or  type I1 diabetes. For 
Table 1. Descriptive statistics for patients fulfilling conventional criteria (absolute and relative) for median rnononeuropathy 
Type of diabetes 
Type I Type II 
Abnormal Normal Abnormal Normal 
Characteristic (N = 31) (N = 124) P-value (N = 64) (N = 195) P-value 
Age (YO 40.0 (26 0, 58 0) 36.0 (24.0, 58.0) 0.47 56.0 (44.0, 64.0) 56.0 (37 0, 65.0) 0 76 
Duration of 
Duration of neuropathy (yr) 2 3 (0 1, 12.2) 1 4 (0.1, 6.4) 0.014 2.3 (0.1, 10.9) 1 9 (0 1, 7.3) 0.06 
Glycosyiated 
hemoglobin (“h) 10.2 (7.4, 13.8) 9.8 (7.3, 13.9) 0.48 10.0 (6.9, 14.5) 9.7 (6.5, 14.1) 0 76 
Body weight (kg) 74.8(506. 110.7) 73.9(54.9,99.5) 0.44 89.2(60.8, 132.2) 87.5(635,119.3) 028 
Height (cm) 170.2 (154.9, 190.0) 171 8 (154.3, 186.7) 0.34 165.7 (149.9, 185.4) 172.7 (156.2, 187.0) 0 001 
Body mass index 
diabetes (yr) 22.5 (4.0, 31.5) 16.0 (3.2, 32.0) 0.003 8.8 (2.0, 20.0) 7.0 (1 0, 20.0) 0 034 
Wm’) 24.9 (20.2, 39.3) 24.3 (20.1, 33.4) 0.12 32.5 (24.5, 40.9) 29.1 (23.1, 39.6) 0.0008 
Data expressed as median (5th. 95th percentiles) 
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Table 2. Frequencies of median mononeuropathy using 
conventional criteria (absolute and relative). 
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Two-sided Fishers Exact lest was used, otherwise specified 
*Significant relabonship with median rnononeuropathy 
tMantel-Haenszel chi-square test 
both groups, patients with MM had significantly 
lower median sensory amplitudes (type I, 12.1 vs. 
22.7 pV, P = 0.0001; type 11, 10.3 vs. 16.4 pV, 
P = O.OOOl), and significantly longer F-wave la- 
tencies (type I, 30.1 vs. 28.7 ms, P = 0.002; type 11, 
30.1 vs. 29.6 ms, P = 0.002) than the remaining 
patients. Median motor conduction velocities were 
significantly slower for patients with MM. Median 
sensory conduction velocities were slower for pa- 
tients with MM but reached statistical significance 
only for patients with type I1 diabetes mellitus. As 
expected from the selection criteria, median dis- 
tal latencies were significantly longer for patients 
with MM. 
DISCUSSION 
In patients with mild diabetic neuropathy, the 23% 
frequency of MM using conventional electrodiag- 
nostic criteria seems high. However, we do not feel 
that the frequency is overestimated, as others have 
reported a prevalence of CTS in diabetic patients 
as high as 32%, recognizing that the frequency of 
MM is not equivalent to the frequency of CTS.'* 
The cross-sectional study of diabetic neuropathy 
reported by Dyck and associates found electrodi- 
agnostic evidence of asymptomatic MM in 22% of 
insulin-dependent and 29% of non-insulin- 
dependent diabetic patients. ** The overall preva- 
lence of 27% of asymptomatic MM is similar to the 
frequency we report, although we may have un- 
derestimated the frequency of MM in diabetic pa- 
tients by including only standard evaluations, as 
well as by excluding patients with severe neuropa- 
thy and patients with greater than mild symptoms 
of CTS. Therefore, our data which are not derived 
from an epidemiologic study of CTS do not resolve 
the controversy related to the prevalence of 
asymptomatic MM in patients with diabetes melli- 
tus. Nevertheless, had our population included a 
substantial number of patients with symptomatic 
CTS, it might be expected that the frequency of 
MM would have exceeded the prevalence of 
asymptomatic MM reported by Dyck and associates 
in their cross-sectional study. As an additional in- 
dication of the small proportion of patients with 
clinically significant CTS, only 1 of the 414 patients 
patients (0.2%) underwent CTS surgery on the 
studied nerve during the 18-month follow-up pe- 
riod. 
The electrodiagnostic measures we  used are 
consistent with standard practice recommenda- 
tions, and are among those most commonly used to 
confirm the diagnosis of CTS. 1,3314-16 The nerve 
conduction criteria for abnormality were estab- 
lished using 95th (conventional) and 99th (conser- 
vative) percentile values obtained from healthy, 
asymptomatic adults without occupational expo- 
sure to cumulative trauma.22 Previous studies have 
recognized the increased frequency of abnormal 
median conduction findings in diabetic patients. In 
addition, some have argued that the inclusion of 
median nerve results in criteria for diabetic neu- 
ropathy are inappropriate because of difficulty in 
apportioning the contribution of CTS and of neu- 
ropathy to electrophysiologic abnormalities when 
both are present.' The results indicate that iso- 
lated median nerve abnormalities occur frequently 
in patients with mild diabetic neuropathy, even 
when patients with greater than mild CTS are ex- 
cluded. Based on the distribution of median minus 
ulnar latencies, differences as great as 2.0 ms were 
within the 95th percentile for this population of 
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Table 3. Electrophysiology of patients fulfilling conventional criteria (absolute and relative) for median rnononeuropathy. 
Type of diabetes 
Type I Type II 
Nerve conduction Abnormal Normal Abnormal Normal 
study (N = 31) (N = 124) P-value (N = 64) (N = 195) P-value 
Peroneal motor 
Amplitude (mV) 3.5 (0.9, 7.0) 3.9 (0.9,9.2) 0.07 3.6 (1.0, 9.1) 4.2 (1.2, 8.9) 0.74 
Conduction velocity (rnis) 40.5 (35.8, 49.8) 40.3 (31 .O, 48.8) 0.34 40.5 (33.1, 50.0) 40.6 (33 2, 50 0 )  0.57 
Distal latency (ms) 5 1 (3.7, 8.1) 4.8 (3.8, 6.6) 0.44 4.6 (3 7, 6.0) 4.8 (3 4, 6 3) 0.59 
F-wave latency (rns) 54.2 (40.6, 64 4) 53.2 (45.0. 67.6) 0.21 53.1 (42.5, 72 4) 55.1 (43 2, 63.2) 0 77 
Right sural 
Amplitude (WV) 5.0 (0.9, 13.5) 6.0 (1.7, 17.0) 0 43 4.7 (1.5, 14.0) 5 0 (1 6, 14 0 )  0 61 
Conduction velocity (m/s) 40.0 (34.1, 56.0) 41.2 (30 8, 50.0) 0 45 42 1 (32.5, 51.9) 41 2 (30 4, 53.8) 0.96 
Distal latency (ms) 4.3 (3.2, 4.9) 4.3 (3.5, 5.4) 0.47 4.1 (3.4, 5.4) 4.1 (3 3, 5.3) 0 66 
Amplitude (pV) 4.5 (1.1, 12.4) 6.1 (2.3, 17.4) 0.19 4.4 (1 4, 14.0) 5.5 (1 6, 13.3) 0 24 
Conduction velocity (rnis) 41 .O (35.0, 52 3) 41.1 (31.8, 50.0) 0 7 41 2 (32.6, 50.0) 41 2 (32 5, 52 0) 0.79 
Distal latency (rns) 4.2 (3.3, 5.2) 4.2 (3.4, 5.2) 0.6 4.1 (3 3, 5.0) 4.2 (3 4, 5 2) 0 7  
Amplitude (mV) 8.3 (2.6, 13.5) 9 0 (4.3, 13.5) 0.55 7.7 (2.2, 12.5) 7.6 (3 6, 13 4) 0.34 




Distal latency (rns) 4 5 (3.7, 8.4) 3.6 (3.0, 4.4) 0.0001 4.6 (3.8, 5.8) 3.7 (3 0, 4.5) 0.0001 
F-wave latency (rns) 30.1 (26.1,35.1) 28.7(25.0,33.6) 0.002 
Amplitude (pV) 12.1 (4 5, 36.1) 22.7 (7.3. 43.1) 0 0001 10 3 (3 3, 23.4) 16.4 (6 3, 39.2) 0.0001 
Distal latency (ms) 4 6 (3.9, 8.9) 3.4 (3.0, 4.2) 0.0001 4.4 (4.0, 5 7) 3.5 (2.9. 4.2) 0.0001 
30.1 (27.2. 35.6) 29.6 (25.1, 33 6) 
Median sensory 
0 0008 53.9 (39.2, 64 2) 56 3 (47 9, 64 8) Conduction velocity (rnis) 55.1 (46.3, 66.0) 56.8 (47.3, 63.4) 0.27 
Data expressed as median (5th. 95th percentiles) 
patients with mild diabetic neuropathy. Conven- 
tional criteria appear inappropriate to confirm the 
presence of CTS in diabetic patients, and cautious, 
conservative use of electrodiagnostic information 
should be emphasized in diagnosing CTS in dia- 
betic patients with equivocal clinical findings. At 
the very least, these results suggest that patients 
with diabetic neuropathy may require special con- 
sideration when confirming the diagnosis of sus- 
pected CTS. 
The reason for the greater frequency of MM in 
diabetic patients than in nondiabetic control sub- 
jects is unknown. One possibility is an increased 
susceptibility to focal trauma of diseased nerves, 
and some have suggested that focal entrapment 
may be the first manifestation of diabetic neurop- 
athy. l 5  Therefore, any personal cofactors associ- 
ated with CTS, such as exposure to repetitive ac- 
tivities or obesity, could produce focal nerve injury 
at points of increased vulnerability more easily in 
patients with diabetic neuropathy than in normal 
subjects. An increased frequency of MM with in- 
creasing evidence of an underlying neuropathy 
would support this possibility. Stratification of pa- 
tients into groups of differing severity of neurop- 
athy based upon sural or peroneal nerve conduc- 
tion abnormalities did not influence the frequency 
of MM. Comparison of nerve conduction results 
between patients fulfilling conventional criteria for 
MM and the remaining patients demonstrated no 
significant differences for any of the peroneal or 
sural measurements, further indicating that the 
magnitude of the underlying neuropathy could 
not explain the presence of the MM. The  only 
nerve conduction differences related to median 
nerve measures. All were consistent with focal 
slowing and loss of large myelinated fibers produc- 
ing reduced amplitudes (sensory), reduced con- 
duction velocities, and prolonged F-wave latencies. 
It also is possible that patients with diabetic 
neuropathy experience less paresthesias and less 
pain in association with median nerve compression 
and therefore are less likely to have clinically evi- 
dent CTS than otherwise normal individuals with 
similar degree of median nerve compression. This 
decreased awareness could mask clinical recogni- 
tion of CTS and could account for the greater fre- 
quency of M M  in diabetic patients than in control 
subjects, although the frequency of asymptomatic 
MM under these conditions would seemingly in- 
crease in proportion to the degree of underlying 
neuropathy, a finding we could not demonstrate. 
Our finding that the presence of MM was sig- 
nificantly associated with the duration of diabetes 
mellitus but not the type of diabetes or age is con- 
sistent with the observations of Dyck and associ- 
ates." Unlike our current results, they found no 
relationship between MM and gender, whereas we 
found a higher frequency in female than in male 
patients. Gender appeared to influence the diag- 
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nosis in a retrospective-review of 261 patients re- 
ferred for electrodiagnostic evaluation and found 
to have MM; in that study, 3 1 % of female patients 
compared with 23% of male patients had abnormal 
results.24 Others have identified a higher fre- 
quency of CTS in female than in male patients, 
although this difference may relate to other covari- 
ates of nerve conduction measures, including body 
size." 
Several investigators found that patients with 
CTS are heavier and shorter than the general pop- 
,lation.7,9,13,17,23 Others have identified BMI as an 
important cofactor, with obese patients (BMI > 29) 
2.5 times more likely than slender patients (BMI < 
20) to have electrodiagnostic evidence of MM, al- 
though the basis of the association is not under- 
stood.24 Overall, the findings in the general pop- 
ulation relating personal cofactors to development 
of MM are similar to those found for patients with 
type I1 diabetes mellitus. The failure to identify 
similar associations in patients with type I diabetes 
mellitus is unexplained. The trends associating 
height to MM were in a direction similar to that for 
the findings reported above and became signifi- 
cant when the more conservative definition of MM 
was used. The failure to identify a significant rela- 
tionship between BMI and MM in patients with 
type I diabetes mellitus may reflect the distribution 
of BMI in this patient group. 
We used latency criteria of MM that classified 
patients as normal or abnormal. Because some pa- 
tients had borderline results (normal or abnormal), 
we attempted to confirm our findings by identify- 
ing subgroups of patients who fulfilled conven- 
tional criteria for all three trials, as well as patients 
who did not fulfill criteria in any of the three trials. 
We felt that these two groups were most represen- 
tative of patients with and without conventional 
electrodiagnostic evidence of MM, respectively. 
Additional analyses with these selective patient 
groups demonstrated results similar to those re- 
ported above. For type I1 patients, the relation- 
ships between MM and gender, and between MM 
and BMI, although still in the same direction, were 
no longer statistically significant. Patients classified 
as having MM, but who had inconsistent results on 
subsequent trials, resembled patients who did not 
fulfill criteria for MM. This finding is not surpris- 
ing, because these were the patients with border- 
line results who typically would have additional 
studies (e.g., midpalmar studies) and would most 
likely be classified as having equivocal evidence 
of MM. 
Some of our results could reflect the selection 
criteria that attempted to identify a relatively ho- 
mogenous group of patients with mild diabetic 
neuropathy. Confirmation of these findings in the 
general diabetic population requires a more di- 
verse group of patients with respect to diabetic 
neuropath y. 
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